Comparing Selank, Semax and DSIP at Peptide Friend

Three starting questions

The labels anxiety, concentration and sleep make these peptides sound like neighboring answers to everyday problems. Their experiments begin in rather different places. I’m wary of awarding an overall winner when the starting questions do so much of the work.

• Selank, anxiety in patients. A small Russian clinical study reported anxiety relief comparable to a benzodiazepine comparator, without sedation, cognitive impairment or withdrawal in that study.
• Semax, the response of rat brain tissue. BDNF and NGF gene expression changed by region, including a fall in frontal-cortex NGF.
• DSIP, disturbed human sleep. Six chronic insomniacs had reported sleep improvements after an initial period of slight arousal.

Molecules and modifications

Semax and Selank are synthetic seven-amino-acid peptides built from different biological starting points: an ACTH fragment for Semax and tuftsin for Selank. Both have a Pro-Gly-Pro tail added to slow breakdown. DSIP has nine amino acids and occurs naturally, although its receptor, gene and precursor remain unresolved in the review literature.

The DSIP fusion-peptide experiment makes the variant question tangible. In mice with induced insomnia, an engineered molecule outperformed native DSIP. I’d want a discussion of any altered preparation to begin with its own evidence. The NA Selank amidate section addresses the related search language.

Combining compounds

The Selank-plus-diazepam rat result is a specific interaction finding. The commonly discussed Semax–Selank combination lacks a controlled human trial establishing its benefit or safety. Activity across overlapping signaling systems makes a pharmacological interaction plausible; the direction and practical consequences remain uncertain.

To my mind, complementarity is an appealing idea still waiting for a suitable experiment. Separate positive findings cannot establish a combination regimen. Peptide Friend provides no instructions for one.

Prescription status

Semax and Selank have Russian prescription registrations; Semax is also registered in Ukraine. Neither has FDA or EMA drug approval. DSIP has no approved drug product. U.S. prescription access involves a licensed clinician’s assessment and can be declined; compounded medications are not FDA-approved. A research-use label gives no patient-specific clinical assessment.

The current record does not specifically name Selank or DSIP on the WADA list; Semax may fall under its S0 category for non-approved substances. This literature comparison offers no anti-doping clearance. The individual pages address the research and safety questions in more detail.